Inside Scope

Enhance your patient care skills with this season covering select AGA Clinical Practice Updates. This episode shares key insights from the AGA Clinical Practice Update: Diet and Nutritional Therapies (published in the March 2024 issue of Gastroenterology). This episode is hosted by Dr. Jana Al Hashash, chair of the AGA Clinical Practice Update Committee. She is joined by authors -Dr. David Binion, professor of medicine and co-director of the IBD Center, director of nutrition support service, at UPMC Presbyterian Hospital and University of Pittsburgh; co-author of CPU -Dr. James Lewis, professor of medicine and epidemiology at the Perelman School of Medicine at the University of Pennsylvania ; co-author of CPU -Ms. Kelly Issokson, registered dietitian and clinical coordinator of digestive diseases at Cedars-Sinai in Los Angeles To access the full Clinical Practice Update, visit www.gastro.org/CPU.

Enhance your patient care skills with this season covering select AGA Clinical Practice Updates. This episode shares key insights from the AGA Clinical Practice Update: Diagnosis and Management of Cyclic Vomiting Syndrome (published in the September 2024 issue of Gastroenterology). We dive into why gastroenterologists and hepatologists should think about a diagnosis of cyclic vomiting syndrome when seeing patients who report recurrent nausea and vomiting symptoms and discuss strategies for therapy. This episode is hosted by Dr. Kyle Staller, CPU author and member of the AGA Clinical Practice Updates Committee. He is joined by fellow authors: -Dr. David Levinthal, assistant professor of medicine at the University of Pittsburgh and director of the UPMC Neurogastroenterology and Motility Center -Dr. Thangam Venkatesan, professor of internal medicine and head of the neurogastroenterology and motility section at The Ohio State University Wexner Medical Center To access the full Clinical Practice Update, visit www.gastro.org/CPU.

Welcome to our four-episode series: Raising Awareness of Hepatorenal Syndrome Acute Kidney Injury (HRS-AKI). In episode two, our host Muhamad Nadeem Yousaf, MD, speaks with Nikki Duong, MD, to discuss the nomenclature, pharmacological options, and care recommendations for HRS-AKI patients. Each episode of this series corresponds to a journal article from a September 2023 supplement of Clinical Gastroenterology and Hepatology (CGH), the official clinical practice journal of the American Gastroenterological Association, focusing on addressing knowledge gaps in HRS-AKI. To read the related journal articles and claim CME for listening, visit agau.gastro.org. This series is supported by an independent educational grant from Mallinckrodt

Welcome to our four-episode series: Raising Awareness of Hepatorenal Syndrome Acute Kidney Injury (HRS-AKI). In episode three, our host Muhamad Nadeem Yousaf, MD, speaks with Nikhilesh Mazumder, MD, MPH, Shilpa Junna, MD, and Pratima Sharma, MD, MBBS, MS, to discuss initial management of patients with HRS-AKI. They'll explore topics such as the efficacy of non-selective beta-blockers, the recommended plasma expander for those with decompensated cirrhosis, the roles of renal replacement therapy (RRT), TIPS, and extracorporeal liver support system (ELSS), and the significance of liver transplant in the context of HRS-AKI. Each episode of this series corresponds to a journal article from a September 2023 supplement of Clinical Gastroenterology and Hepatology (CGH), the official clinical practice journal of the American Gastroenterological Association, focusing on addressing knowledge gaps in HRS-AKI. To read the related journal articles and claim CME for listening, visit agau.gastro.org. This series is supported by an independent educational grant from Mallinckrodt

Welcome to our four-episode series: Raising Awareness of Hepatorenal Syndrome Acute Kidney Injury (HRS-AKI). In our final episode, our host Muhamad Nadeem Yousaf, MD, speaks with Vivian Ortiz, MD, and Neil Shah, MD, to delve into critical aspects of HRS-AKI. They cover the prognosis after initial management, the significance of reversing renal impairment for liver transplant candidates, the predictive role of MELD score in HRS-AKI, treatment's impact on liver transplant waiting lists, decision-making between liver transplant alone or simultaneous liver-kidney transplant, timing considerations for kidney transplant post-liver transplant, and factors affecting post-transplant prognosis. Each episode of this series corresponds to a journal article from a September 2023 supplement of Clinical Gastroenterology and Hepatology (CGH), the official clinical practice journal of the American Gastroenterological Association, focusing on addressing knowledge gaps in HRS-AKI. To read the related journal articles and claim CME for listening, visit agau.gastro.org. This series is supported by an independent educational grant from Mallinckrodt

Welcome to our four-episode series: Raising Awareness of Hepatorenal Syndrome Acute Kidney Injury (HRS-AKI). In episode one, our host Muhamad Nadeem Yousaf, MD, speaks with Danielle Adebayo, MD, and Florence Wong, MD, MBBS, FRCPC, to analyze the pathophysiology of HRS-AKI. They cover peripheral vasodilatation hypothesis shortcomings in HRS-AKI, vasoconstrictor systems, bacterial translocation, inflammation, renal dysfunction, and contributory factors like cholemic nephropathy and adrenal insufficiency, while also suggesting the potential of metabolomic studies for future insights. Each episode of this series corresponds to a journal article from a September 2023 supplement of Clinical Gastroenterology and Hepatology (CGH), the official clinical practice journal of the American Gastroenterological Association, focusing on addressing knowledge gaps in HRS-AKI. To read the related journal articles and claim CME for listening, visit agau.gastro.org. This series is supported by an independent educational grant from Mallinckrodt

This special episode of Inside Scope shares key insights from the AGA Clinical Practice Update on Alpha-Gal Syndrome for the GI Clinician. This episode is hosted by Dr. Jana Al Hashash, chair-elect of the AGA Clinical Practice Update Committee and one of the CPU authors. She is joined by: Sarah McGill, MD, MSc, gastroenterologist and associate professor of medicine at the University of North Carolina and lead author of the CPU Thomas Platts-Mills, MD, professor of medicine and microbiology and chief at the University of Virginia, a pioneer in discovery of Alpha Gal Syndrome and senior author of the CPU Hannah Dodson, DNP, nurse Practitioner affiliated with the University of North Carolina and a patient sharing her perspective in navigating life with Alpha Gal Syndrome To access the CPU commentary, visit https://www.cghjournal.org/article/S1542-3565(23)00040-X/fulltext

Dr. G.S. Raju, editor of the Gastro Grand Rounds section in Gastroenterology, is joined by Drs. Marwan Ghabril and Naga Chalasani to discuss their Gastro Grand Rounds article, "A 68-Year-Old Woman With Unexplained Liver Enzyme Elevation and Active Chronic Hepatitis: Beware of Drug-Induced Autoimmune-Like Hepatitis." https://www.gastrojournal.org/article/S0016-5085(23)05078-3/fulltext Dr. Ghabril is a professor of medicine at Indiana University School of Medicine. Dr. Chalasani is the David W. Crabb professor of gastroenterology and hepatology and an adjunct professor of anatomy, cell biology, and physiology at Indiana University School of Medicine. [0:27] Introduction of the authors and outline of the case. [3:30] Initial thoughts from the authors upon patient presentation. [7:29] After considering additional patient history, what do the authors think about the patient? [10:34] Does the family history of the patient cause the authors to refine the diagnosis? [11:52] Further thoughts from the authors after physical examination of the patient. [14:47] What tests are recommended? [18:55] Additional thoughts from the authors after further testing. [21:06] Should we be testing for hepatitis E? [22:56] Should noninvasive testing be used? [25:11] What is the authors' plan to determine next steps? [27:06] How long should the wait be before a biopsy? [29:08] The patient underwent liver biopsy. How were the results interpreted? [34:31] How long does it take to determine that an appropriate course of action was made? [35:37] How is the patient counselled? [38:43] The LiverTox database. [41:41] Final thoughts from the authors. Thank you for listening. Find this and other articles on our website at https://www.gastrojournal.org. We welcome your feedback. Please email us at gastro@gastro.org. This discussion was recorded on Dec. 20, 2023, and reflects medical knowledge at that time. The views and opinions expressed in this podcast are those of the individual speakers only and do not necessarily represent those of the American Gastroenterological Association. The content of this podcast is provided for general information purposes only and does not offer medical or any other type of professional advice.

Welcome to our six-part series: Increasing Diversity in IBD Clinical Trials. This program will explore how to become a clinical trialist and increase diversity in IBD clinical trials. In this supersized episode, co-host Dr. Ayanna Lewis is joined by guest Dr. Ryan Stidham, an associate professor at the University of Michigan holding appointments in the departments of medicine and computational medicine. Dr. Stidham is a medical data scientist and has a research program that focuses on the development and testing of new technologies for disease assessment and decision making in gastroenterology and general medicine. Today's discussion will explore how artificial intelligence may help address challenges with participant recruitment for clinical trials, while also discussing the role of AI in the field of gastroenterology more broadly. This series is supported by educational grants from AbbVie Inc.; Amgen; Bristol-Myers Squibb Company; Genentech, a member of the Roche Group; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Pharmaceuticals U.S.A., Inc., and a quality improvement grant from Pfizer Inc.

Welcome to our six-part series: Increasing Diversity in IBD Clinical Trials. This program will explore how to become a clinical trialist and increase diversity in IBD clinical trials. In this episode, co-host Dr. Ayanna Lewis is joined by guest Dr. Erica Cohen, an adult gastroenterologist, IBD specialist and director of the IBD Research Program at Capital Digestive Care in Washington, D.C. Today's discussion focuses on the community GI's perspective on clinical trials. This series is supported by educational grants from AbbVie Inc.; Amgen; Bristol-Myers Squibb Company; Genentech, a member of the Roche Group; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Pharmaceuticals U.S.A., Inc., and a quality improvement grant from Pfizer Inc.

Welcome to our six-part series: Increasing Diversity in IBD Clinical Trials. This program will explore how to become a clinical trialist and increase diversity in IBD clinical trials. In this episode, co-host Dr. Erin Forster is joined by guest Kenneth Getz, professor of public health and community medicine and director of the Center for the Study of Drug Development at Tufts University School of Medicine. Ken is also the founder and chairman of the board of directors at CISCRP, a nonprofit dedicated to providing education and information about clinical research. Today's discussion will explore how we can bring awareness of and education on clinical research to the community. This series is supported by educational grants from AbbVie Inc.; Amgen; Bristol-Myers Squibb Company; Genentech, a member of the Roche Group; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Pharmaceuticals U.S.A., Inc., and a quality improvement grant from Pfizer Inc.

Welcome to our six-part series: Increasing Diversity in IBD Clinical Trials. This program will explore how to become a clinical trialist and increase diversity in IBD clinical trials. In this episode, co-host Dr. Erin Forster is joined by guest Dr. Gabriela Radulescu, vice president of medical research and development at Alimentiv, a contract research organization (CRO) specializing in gastroenterology trials. Dr. Radulescu has more than 20 years of experience working in the pharmaceutical industry across multiple functions, including medical affairs, drug safety and pharmacovigilance, clinical research, real world evidence, and patient support programs. At Alimentiv, Dr. Radulescu provides medical leadership for sponsored clinical trials, operational oversight for R&D projects, and medical input to the business development teams. Today's discussion will explore how CROs are working with investigators and sponsors to increase the diversity of patients enrolling in clinical trials. This series is supported by educational grants from AbbVie Inc.; Amgen; Bristol-Myers Squibb Company; Genentech, a member of the Roche Group; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Pharmaceuticals U.S.A., Inc., and a quality improvement grant from Pfizer Inc.

Welcome to our six-part series: Increasing Diversity in IBD Clinical Trials. This program will explore how to become a clinical trialist and increase diversity in IBD clinical trials. In this episode, hosts Drs. Erin Forster and Ayanna Lewis are joined by Melodie Narain-Blackwell, the founder and president of Color of Crohn's & Chronic Illness (COCCI). COCCI is a nonprofit dedicated to health equity in BIPOC communities that are challenged with digestive diseases and chronic illnesses. Melodie was diagnosed with Crohn's disease at the age of 36, thirty years after her symptoms began, and has become a passionate health advocate for people of color who battle chronic illness. Today's discussion focuses on how we talk about clinical research with patients. This series is supported by educational grants from AbbVie Inc.; Amgen; Bristol-Myers Squibb Company; Genentech, a member of the Roche Group; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Pharmaceuticals U.S.A., Inc., and a quality improvement grant from Pfizer Inc.

Welcome to our six-part series: Increasing Diversity in IBD Clinical Trials. This program will explore how to become a clinical trialist and increase diversity in IBD clinical trials. In this episode, hosts Drs. Erin Forster and Ayanna Lewis are joined by Drs. Freddy Caldera and Jana Al Hashash, who were part of the inaugural class of participants in AGA's GI Clinical Trialists Bootcamp program. Today's discussion focuses on how diversifying participation in clinical trials starts with diversifying our workforce. This series is supported by educational grants from AbbVie Inc.; Amgen; Bristol-Myers Squibb Company; Genentech, a member of the Roche Group; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Pharmaceuticals U.S.A., Inc., and a quality improvement grant from Pfizer Inc.

Dr. G.S. Raju, editor of the Gastro Grand Rounds section in Gastroenterology, is joined by Dr. David Ballard and Dr. Parakkal Deepak to discuss their Gastro Grand Rounds article, "Long-Standing Symptomatic Fistulizing Perianal Crohn's Disease: Progression Beyond Inflammation." https://www.gastrojournal.org/article/S0016-5085(23)04997-1/fulltext Dr. Ballard is an assistant professor of radiology and director of the 3D Printing Lab at the Mallinckrodt Institute of Radiology at Washington University School of Medicine in St. Louis. Dr. Deepak is an Associate Professor of Medicine in the Division of Gastroenterology at Washington University School of Medicine in St. Louis. [0:27] Introduction of the authors and outline of the case. [2:29] What initial steps does a gastroenterologist take to manage a patient who presents with possible perianal Crohn's disease? [6:47] How does an imaging specialist plan for imaging of the perianal disease, and what techniques are used in support of the endoscopist or gastroenterologist? [11:33] The role of point-of-care ultrasound in perianal disease. [15:38] When is a colorectal surgeon brought on board, and what does a colorectal surgeon do when examining the patient? [19:57] How does the clinician manage abscess and fistula? [25:13] Are there any radiological signs that indicate that a particular fistula may be particularly difficult to manage? [29:38] What is a standard treatment for perianal fistula that evolves to cancer? [31:27] Did the patient notice a change in the nature of the discharge? [32:35] Final thoughts from the authors. Thank you for listening. Find this and other articles on our website at https://www.gastrojournal.org. We welcome your feedback. Please email us at gastro@gastro.org. This discussion was recorded on Nov. 1, 2023, and reflects medical knowledge at that time. The views and opinions expressed in this podcast are those of the individual speakers only and do not necessarily represent those of the American Gastroenterological Association. The content of this podcast is provided for general information purposes only and does not offer medical or any other type of professional advice.

Welcome to the first in a series of new podcast episodes from the pages of Gastroenterology, the flagship journal of the American Gastroenterological Association and the most prominent journal in the field of gastrointestinal disease. This podcast series covers articles in the journal's “Gastro Grand Rounds” section, which features discussions among multidisciplinary teams of experts on the management of complex clinical cases. Gastro Grand Rounds: Managing Diverticulitis Dr. G.S. Raju, editor of the Gastro Grand Rounds section in Gastroenterology, is joined by Dr. Lisa Strate to discuss her article, “Recurrent Lower Abdominal Pain, Altered Bowel Habits, and Malaise: Conservative or Surgical Approach to a Common Disorder.” https://www.gastrojournal.org/article/S0016-5085(23)00042-2/fulltext Dr. Strate is a professor of medicine at the University of Washington School of Medicine and is the section head of gastroenterology at Harborview Medical Center. Dr. Strate's research has examined risk factors for the development of diverticular disease. Her work has informed the development of guidelines, dietary recommendations, and measurements for the prevention of diverticulitis. She has investigated the role of chronic inflammation and the gut microbiome in diverticulitis. She is a fellow of AGA. [0:27] Introduction of the author. [2:20] The utility of CT in evaluating diverticulitis. [5:49] Managing a patient with uncomplicated diverticulitis. [11:00] Take-home instructions for the patient. [14:12] Preparing the patient colonoscopy, strategies used during the procedure, and documenting findings. [19:11] Utility of a barium enema. [20:22] The patient returns and has left lower quadrant pain. What are the next steps? [24:30] Laying out the pros and cons of continued medical management compared with surgery for a patient who has recurrent episodes of uncomplicated diverticulitis. [28:00] Does the author's institution have a support group for patients? [28:55] What is the longest period of antibiotics the author has given to a patient who does not want surgery? [30:34] Take-home messages for fellows and residents. Thank you for listening. Find this and other articles on our website at https://www.gastrojournal.org. We welcome your feedback. Please email us at gastro@gastro.org. This discussion was recorded on Sept. 5, 2023, and reflects medical knowledge at that time. The views and opinions expressed in this podcast are those of the individual speakers only and do not necessarily represent those of the American Gastroenterological Association. The content of this podcast is provided for general information purposes only and does not offer medical or any other type of professional advice.

Welcome to our new six-episode series: C. difficile: Preparing the Field for Change. This program will explore how to take a patient-centered approach to treatment and diagnosis, explore emerging treatment options, and discuss best practices for transitions of care. In this episode, Drs. Paul Feuerstadt and Sahil Khanna are joined by guest Dr. Jessica Allegretti to discuss FMT and new microbiome therapies. You can now claim CME for listening – visit agau.gastro.org. This series is supported by educational grants from Aimmune Therapeutics, Inc., Seres Therapeutics, and Ferring Pharmaceuticals, Inc.

Welcome to our new six-episode series: C. difficile: Preparing the Field for Change. This program will explore how to take a patient-centered approach to treatment and diagnosis, explore emerging treatment options, and discuss best practices for transitions of care. In this episode, Drs. Paul Feuerstadt and Sahil Khanna are joined by guests Drs. Kevin Garey and Melissa Passarello to discuss the impact of recurrent CDI on patients and their lives. This episode does not offer Continuing Medical Education (CME) credits. This series is supported by educational grants from Aimmune Therapeutics, Inc., Seres Therapeutics, and Ferring Pharmaceuticals, Inc.

Welcome to our new six-episode series: C. difficile: Preparing the Field for Change. This program will explore how to take a patient-centered approach to treatment and diagnosis, explore emerging treatment options, and discuss best practices for transitions of care. In this episode, Drs. Paul Feuerstadt and Sahil Khanna are joined by guests Rebecca Perez and Cheri Lattimer to discuss case management and transitions of care in C. difficile infection. You can now claim CME for listening – visit agau.gastro.org. This series is supported by educational grants from Aimmune Therapeutics, Inc., Seres Therapeutics, and Ferring Pharmaceuticals, Inc.

Welcome to our new six-episode series: C. difficile: Preparing the Field for Change. This program will explore how to take a patient-centered approach to treatment and diagnosis, explore emerging treatment options, and discuss best practices for transitions of care. In this episode, Drs. Paul Feuerstadt and Sahil Khanna are joined by guest Dr. Colleen Kelly to discuss how to reconcile guideline differences for testing and treatment of C. difficile. You can now claim CME for listening – visit agau.gastro.org. This series is supported by educational grants from Aimmune Therapeutics, Inc., Seres Therapeutics, and Ferring Pharmaceuticals, Inc.

Welcome to our new six-episode series: C. difficile: Preparing the Field for Change. This program will explore how to take a patient-centered approach to treatment and diagnosis, explore emerging treatment options, and discuss best practices for transitions of care. In this episode, Drs. Paul Feuerstadt and Sahil Khanna describe the shifts in the microbiota with C. difficile infection. This episode was originally released as a bonus episode in November 2022. You can now claim CME for listening – visit agau.gastro.org. This series is supported by educational grants from Aimmune Therapeutics, Inc., Seres Therapeutics, and Ferring Pharmaceuticals, Inc.

Welcome to our new six-part series: C. difficile: Preparing the Field for Change. This program will explore how to take a patient-centered approach to treatment and diagnosis, explore emerging treatment options, and discuss best practices for transitions of care. In this episode, Drs. Paul Feuerstadt and Sahil Khanna cover risk factors for initial and recurrent C. difficile infection. This episode was originally released as a bonus episode in November 2022. You can now claim CME for listening – visit agau.gastro.org. This series is supported by educational grants from Aimmune Therapeutics, Inc., Seres Therapeutics, and Ferring Pharmaceuticals, Inc.

This special episode of Inside Scope shares recommendations from the AGA Clinical Practice Update (CPU) on the Endoscopic Approach to Recurrent Acute and Chronic Pancreatitis. Our host Jana Al Hashash, MD, is joined by subject matter expert Greg Cote, MD, MS, and CPU authors Daniel Strand, MD, and Ryan Law, DO.

Welcome to the final episode of our series Innovation in Duodenoscope Design. Guest host Nina Nandy, MD, is joined by Michael L. Kochman, MD, AGAF, to discuss the recently published multisociety guideline on reprocessing flexible GI endoscopes and if the recommendations put forth are sufficient to address the current challenges posed by duodenoscope-related infections. This series is supported by an unrestricted educational grant from Boston Scientific. To find additional resources and learn more about Innovation in Duodenoscope Design, visit scopeinnovation.gastro.org.

Episode 2 of our new series Innovation in Duodenoscope Design is all about disposable scopes! Join host Adarsh Thaker, MD, and his guests Gregory A. Cote, MD, and Andrew Ross, MD, as they cover: • How to determine whether a scope is clean or not and how to know it is ready for the next patient. • Cost and reimbursement factors into declaring that the risk of exogenous is "low". • If single use duodenoscopes make sense not only in infection prevention but also in the cost to the environment. This series is supported by an unrestricted educational grant from Boston Scientific. To find additional resources and learn more about Innovation in Duodenoscope Design, visit scopeinnovation.gastro.org.

Welcome to our new series Innovation in Duodenoscope Design! Episode one is hosted by Adarsh Thaker, MD. He is joined by Shani Haugen, PhD, who will help us understand how the FDA is addressing duodenoscope-related infection issues. They'll answer key questions like what do FDA's Safety Communications mean for GIs, what have we learned from 522 studies, and what do we still have to learn? This series is supported by an unrestricted educational grant from Boston Scientific. To find additional resources and learn more about Innovation in Duodenoscope Design, visit scopeinnovation.gastro.org.

Uzma Siddiqui, MD, is here to host episode 3 of our series Innovation in Duodenoscope Design! She's joined by Amrita Sethi, MD, to discuss opportunities with single-use scopes beyond infection control, with a focus on ergonomic design. They'll talk through how disposable scopes impact workflow both on and off the unit. Continue listening for a discussion on advantages and disadvantages of the widespread use of disposable scopes now and in the future. This series is supported by an unrestricted educational grant from Boston Scientific. To find additional resources and learn more about Innovation in Duodenoscope Design, visit scopeinnovation.gastro.org.

This special episode of Inside Scope shares key insights from the AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease. This episode is hosted by Dr. Jana Al Hashash, member of the AGA Clinical Practice Update Committee. She is joined by: -Dr. Heather Patton, NAFLD expert and past member of the AGA Clinical Practice Update Committee -Dr. Joseph K. Lim, past chair of the AGA Clinical Practice Update Committee and co-author of this CPU -Dr. Zobair M Younossi, co-author of this CPU To access the full expert review, visit www.gastro.org/CPU.

Welcome to our four-part series Biosimilars: Addressing the Knowledge Gaps, hosted by Dr. Christina Ha. Each episode features a challenging patient case and short discussion. In episode 3 of 4, we're joined by guests Shuba Bhat, PharmD, and Jennifer Seminerio-Diehl, MD, to discuss: • What are the practical logistics when you work on a switch with a patient? • How do you address a situation where a patient says they are experiencing an increase in symptoms after a switch? • Are there any situations where you would consider appealing an insurance decision and not switching? • What tests do you use to determine whether a patient is experiencing active disease before or after a switch? This series is supported by independent medical education grants from Amgen and Pfizer. To collect CME credit for listening, visit agau.gastro.org.

Welcome to our four-part series Biosimilars: Addressing the Knowledge Gaps, hosted by Dr. Christina Ha. Each episode features a challenging patient case and short discussion. In episode 4 of 4, we're joined by guests Shuba Bhat, PharmD, and Miguel Regueiro, MD, to discuss: • Their approach to shared decision-making with a patient that's concerned about a switch. And how often does this occur? • Do you suggest that the patient speak with multiple team members? • As a clinical pharmacist how do you counsel these patients? • What is the general approach to switching used at Cleveland Clinic and what do you find has been most helpful? This series is supported by independent medical education grants from Amgen and Pfizer. To collect CME credit for listening, visit agau.gastro.org.

Welcome to our four-part series Biosimilars: Addressing the Knowledge Gaps, hosted by Drs. Christina Ha and Frank Scott. Each episode features a challenging patient case and short discussion. In episode 2 of 4, we'll discuss: • How do you prepare your team and the patient for a switch to a biosimilar? • Are there any situations where switching is not appropriate? • What do you think about multiple switches? • How do you minimize the potential for a nocebo effect? This series is supported by independent medical education grants from Amgen and Pfizer. To collect CME credit for listening, visit agau.gastro.org.

Welcome to our four-part series Biosimilars: Addressing the Knowledge Gaps, hosted by Drs. Christina Ha and Frank Scott. Each episode features a challenging patient case and short discussion. In episode 1 of 4, we'll discuss: • How do you explain biosimilars to a patient with moderate-to-severe Crohn's disease when you start them on a biologic? • What are some of the common questions that patients ask and how do you address them? • Do you set goals of therapy with your patients and what are they? This series is supported by independent medical education grants from Amgen and Pfizer. To collect CME credit for listening, visit agau.gastro.org.

This is episode 1 of our 5-part series Colorectal Cancer: Screening to Save Lives. This episode covers what clinicians need to know regarding the updated colorectal cancer screenings guidance from the U.S. Preventive Services Task Force. In this episode: • David Lieberman, MD, professor of medicine in the division of gastroenterology and hepatology at the Oregon Health & Science University • Chyke Doubeni, MD, chief health equity officer for the Ohio State University Wexner Medical Center and associate director for diversity, equity and inclusion for The Ohio State University Comprehensive Cancer Center This season is supported by an independent medical education grant from Exact Sciences.

This is episode 2 of our 5-part series Colorectal Cancer: Screening to Save Lives. This episode is about strategies for promoting initiation of colorectal cancer screening at age 45 and addressing early-onset colorectal cancer. In this episode: • David Lieberman, MD, professor of medicine in the division of gastroenterology and hepatology at the Oregon Health & Science University • Chyke Doubeni, MD, chief health equity officer for the Ohio State University Wexner Medical Center and associate director for diversity, equity and inclusion for The Ohio State University Comprehensive Cancer Center • Samir Gupta, MD, associate professor of clinical medicine at the University of California San Diego and the San Diego Veterans Affairs Healthcare System This season is supported by an independent medical education grant from Exact Sciences.

This is episode 3 of our 5-part series Colorectal Cancer: Screening to Save Lives. This episode is about the importance of primary care providers in identifying and managing patients at high risk for colorectal cancer. In this episode: • David Lieberman, MD, professor of medicine in the division of gastroenterology and hepatology at the Oregon Health & Science University • Chyke Doubeni, MD, chief health equity officer for the Ohio State University Wexner Medical Center and associate director for diversity, equity and inclusion for The Ohio State University Comprehensive Cancer Center • Swati Patel, MD, associate professor and director of the Gastrointestinal Cancer Risk and Prevention Center at the University of Colorado School of Medicine Anschutz Medical Campus. This season is supported by an independent medical education grant from Exact Sciences.

This is episode 4 of our 5-part series Colorectal Cancer: Screening to Save Lives. We talk about important considerations when caring for individuals at high risk for poor outcomes in colorectal cancer due to social determinants of health. In this episode: • David Lieberman, MD, professor of medicine in the division of Gastroenterology and Hepatology at the Oregon Health & Science University • Chyke Doubeni, MD, chief health equity officer for the Ohio State University Wexner Medical Center and associate director for diversity, equity and inclusion for The Ohio State University Comprehensive Cancer Center This season is supported by an independent medical education grant from Exact Sciences.

In our final episode of our 5-part series Colorectal Cancer: Screening to Save Lives, we share updated information about coverage, cost-sharing, reimbursement and coding for colorectal cancer screening. In this episode: • David Lieberman, MD, professor of medicine in the division of gastroenterology and hepatology at the Oregon Health & Science University • Chyke Doubeni, MD, chief health equity officer for the Ohio State University Wexner Medical Center and associate director for diversity, equity and inclusion for The Ohio State University Comprehensive Cancer Center • Shivan Mehta, MD, assistant professor of medicine and health policy at Perelman School of Medicine and associate chief innovation officer at Penn Medicine Center for Innovation This season is supported by an independent medical education grant from Exact Sciences.

This is episode 6 of 6 from our program: Obesity in GI Care: Start the Conversation, Change the Narrative. Over the course of 6 podcast episodes and 3 webinars, you'll learn a comprehensive approach to diagnosing and treating obesity, with a specific focus on patients with GI comorbidities. This series highlights key findings and strategies from AGA's 2017 Practice guide on Obesity and Weight management, Education and Resources (POWER program). In this episode, our hosts Drs. Andres Acosta and Octavia Pickett-Blakely discuss: • The role of the gastroenterologists and hepatologists, gastroenterology and hepatology advanced practice providers (APP), and others in a care team for obesity management. • How to find information on coding and reimbursement for obesity management. • How treating obesity is beneficial for patients and practices. • Pearls from episodes 1-5 of the series. To collect CME credit for listening, visit agau.gastro.org.

This is episode 5 of 6 from our program: Obesity in GI Care: Start the Conversation, Change the Narrative. Over the course of 6 podcast episodes and 3 webinars, you'll learn a comprehensive approach to diagnosing and treating obesity, with a specific focus on patients with GI comorbidities. This series highlights key findings and strategies from AGA's 2017 Practice guide on Obesity and Weight management, Education and Resources (POWER program). In this episode, our host Dr. Andres Acosta is joined by Dr. John Magaña Morton to discuss: • Evaluating patient outcomes and measuring weight loss success in terms of reduced disease burden. • How to adapt treatment plans when interventions are unsuccessful. • The future of obesity care in gastroenterology. To collect CME credit for listening, visit agau.gastro.org.

This is episode 4 of 6 from our program: Obesity in GI Care: Start the Conversation, Change the Narrative. Over the course of 6 podcast episodes and 3 webinars, you'll learn a comprehensive approach to diagnosing and treating obesity, with a specific focus on patients with GI comorbidities. This series highlights key findings and strategies from AGA's 2017 Practice guide on Obesity and Weight management, Education and Resources (POWER program). In this episode, our host Dr. Andres Acosta is joined by Dr. Barham Abu Dayyeh to discuss: • Gastroenterologists and the GI care team should embrace obesity care as weight management is proven to be beneficial in patients with comorbid gastrointestinal (GI) diseases, such as nonalcoholic fatty liver disease (NAFLD), reflux esophagitis, gastroesophageal reflux disease (GERD), gallbladder disease, pancreatitis, esophageal and colon cancer. • Gastroenterologists and the GI care team are poised to offer comprehensive care for patients with obesity who may require endoscopic procedures and/or bariatric surgery to achieve long term weight loss. • Updates on devices for obesity management that are available now and a look into what may be available in the future. To collect CME credit for listening, visit agau.gastro.org.

This is episode 3 of 6 from our program: Obesity in GI Care: Start the Conversation, Change the Narrative. Over the course of 6 podcast episodes and 3 webinars, you'll learn a comprehensive approach to diagnosing and treating obesity, with a specific focus on patients with GI comorbidities. This series highlights key findings and strategies from AGA's 2017 Practice guide on Obesity and Weight management, Education and Resources (POWER program). In this episode, our host Dr. Andres Acosta is joined by Dr. Janese Laster to discuss: • Gastroenterologists and the GI care team should embrace obesity care as weight management is proven to be beneficial in patients with comorbid gastrointestinal (GI) diseases, such as nonalcoholic fatty liver disease (NAFLD), reflux esophagitis, gastroesophageal reflux disease (GERD), gallbladder disease, pancreatitis, esophageal and colon cancer. • Gastroenterologists and the GI care team are poised to offer comprehensive care for patients with obesity who may require endoscopic procedures and/or bariatric surgery to achieve long term weight loss. • Updates on medications for obesity management that are available now and a look into what may be available in the future. To collect CME credit for listening, visit agau.gastro.org.

This is episode 2 of 6 from our new program: Obesity in GI Care: Start the Conversation, Change the Narrative. Over the course of 6 podcast episodes and 3 webinars, you'll learn a comprehensive approach to diagnosing and treating obesity, with a specific focus on patients with GI comorbidities. This series highlights key findings and strategies from AGA's 2017 Practice guide on Obesity and Weight management, Education and Resources (POWER program). In this episode, our hosts Drs. Andres Acosta and Octavia Pickett-Blakely are joined by Dr. Colleen Tewksbury to discuss: • A deep dive into dietary approaches for obesity management including debating low carb versus low fat diets. • Misconceptions that society has about dietary approaches to weight loss. • The importance of an individualized approach versus a cure-all for everyone. To collect CME credit for listening, visit agau.gastro.org.

This is episode 1 of 6 from our new program: Obesity in GI Care: Start the Conversation, Change the Narrative. Over the course of 6 podcast episodes and 3 webinars, you'll learn a comprehensive approach to diagnosing and treating obesity, with a specific focus on patients with GI comorbidities. This series highlights key findings and strategies from AGA's 2017 Practice guide on Obesity and Weight management, Education and Resources (POWER program). In this episode, our hosts Drs. Andres Acosta and Octavia Pickett-Blakely are joined by Dr. Naresh Gunaratnam to discuss: • Weight management is proven to be beneficial in patients with comorbid gastrointestinal (GI) diseases, such as nonalcoholic fatty liver disease (NAFLD), reflux esophagitis, gastrointestinal reflux disease (GERD), gallbladder disease, pancreatitis, esophageal and colon cancer. • Gastroenterologists and the GI care team are poised to offer comprehensive care for patients with obesity who may require endoscopic procedures and/or bariatric surgery to achieve long term weight loss. To collect CME credit for listening, visit agau.gastro.org.

This is episode 1 of our 6-part podcast, NASH: Take Action!, where leaders in gastroenterology, hepatology, endocrinology and primary care talk about the real-world, practical implications of screening, diagnosing and managing people with NAFLD and NASH. This series is hosted by Drs. Fasiha Kanwal, Kenneth Cusi and Jay H. Shubrook. We start with a discussion on the prevalence of NAFLD and NASH and their clinical and economic burdens with guest Zobair Younossi, MD, president, medicine service line, Inova Health System. To collect CME credit for listening, visit nash.gastro.org.

Lee Kaplan, MD, founding director of the Weight Center at Massachusetts General Hospital, discusses the relationship between NASH, obesity and associated comorbidities. This is episode 2 of our 6-part podcast, NASH: Take Action!, where leaders in gastroenterology, hepatology, endocrinology and primary care discuss the real-world, practical implications of screening, diagnosing and managing people with NAFLD and NASH. This series is hosted by Drs. Fasiha Kanwal, Kenneth Cusi and Jay H. Shubrook. To collect CME credit for listening, visit nash.gastro.org.

Kim Pfotenhauer, DO, Michigan State University, and Eugene Wright, MD, Duke University, discuss screening people for NAFLD in the primary care setting. This is episode 3 of our 6-part podcast, NASH: Take Action!, where leaders in gastroenterology, hepatology, endocrinology and primary care discuss the real-world, practical implications of screening, diagnosing and managing people with NAFLD and NASH. This series is hosted by Drs. Fasiha Kanwal, Kenneth Cusi and Jay H. Shubrook. To collect CME credit for listening, visit nash.gastro.org.

Vincent Wong, MD, The Chinese University of Hong Kong, provides insights into noninvasive diagnostic techniques for patients at high risk for NASH and the role of liver biopsy in diagnosing NASH. This is episode 4 of our 6-part podcast, NASH: Take Action!, where leaders in gastroenterology, hepatology, endocrinology and primary care discuss the real-world, practical implications of screening, diagnosing and managing people with NAFLD and NASH. This series is hosted by Drs. Fasiha Kanwal, Kenneth Cusi and Jay H. Shubrook. To collect CME credit for listening, visit nash.gastro.org.

Robert H. Eckel, MD, University of Colorado, discusses limitations in current data about managing NAFLD and NASH and emerging therapies. This is episode 5 of our 6-part podcast, NASH: Take Action!, where leaders in gastroenterology, hepatology, endocrinology and primary care discuss the real-world, practical implications of screening, diagnosing and managing people with NAFLD and NASH. This series is hosted by Drs. Fasiha Kanwal, Kenneth Cusi and Jay H. Shubrook. To collect CME credit for listening, visit nash.gastro.org.

We close out this series chatting with Hashem El-Serag, MD, Baylor College of Medicine, about collaboration between primary care providers and specialists in managing patients with NAFLD and NASH. This is the final episode in our 6-part podcast, NASH: Take Action!, where leaders in gastroenterology, hepatology, endocrinology and primary care discuss the real-world, practical implications of screening, diagnosing and managing people with NAFLD and NASH. This series is hosted by Drs. Fasiha Kanwal, Kenneth Cusi and Jay H. Shubrook. To collect CME credit for listening, visit nash.gastro.org.

The NASH: Take Action! six-episode podcast series features interviews with world-renowned experts in NAFLD, NASH and metabolic syndrome providing practical information for health care professionals on screening, diagnosing and managing these conditions. Collect up to 6 AMA PRA Category 1 credits for this activity by visiting nash.gastro.org.